卵巢癌组织中FBXO31、PROX1表达及与病理特征、预后的相关性研究

Expression of FBXO31 and PROX1 in ovarian cancer tissues and their correlations with pathological features and prognosis

摘要

目的 研究卵巢癌组织中F-box蛋白31(FBXO31)、Prospero相关同源盒蛋白1(PROX1)表达与患者病理特征、预后的相关性,为患者的病理风险评估、预后预测及潜在治疗靶点挖掘提供理论依据。方法 选取2019年1月至2021年6月本院收治的卵巢癌患者138例,根据是否死亡分为死亡组(n=59)、存活组(n=79)。利用免疫组化法检测FBXO31、PROX1表达;采用Cox回归筛选患者死亡的影响因素;利用Kaplan-Meier分析FBXO31、PROX1表达对卵巢癌患者生存率的影响。结果 卵巢癌组织中FBXO31阴性表达、PROX1阳性表达的比例较高(χ²=50.274、83.781,P＜0.05)。在低分化、有淋巴结转移以及TNM分期为Ⅲ~Ⅳ期的患者中,FBXO31的阴性表达比例更高(χ²:4.524~12.644,P＜0.05),而PROX1的阳性表达比例更高(χ²:6.072~10.107,P＜0.05)。卵巢癌患者的预后与年龄、肿瘤大小、病理分型无关(P＞0.05),而低分化(HR=1.756,95%CI:1.212~2.543)、淋巴结转移(HR=2.122,95%CI:1.398~3.221)、TNM Ⅲ~Ⅳ期(HR=2.472,95%CI:1.590~3.842)、FBXO31阴性(HR=2.583,95%CI:1.735~3.845)以及PROX1阳性(HR=2.044,95%CI:1.274~3.278)均与死亡风险升高相关(P＜0.05)。FBXO31阴性表达生存率49.09%低于阳性89.29%(P＜0.05),PROX1阳性表达生存率48.57%低于阴性84.85%(P＜0.05)。结论 卵巢癌组织中FBXO31、PROX1表达与卵巢癌病理特征有关,FBXO31、PROX1是卵巢癌患者预后的影响因素。

Abstract

Objective To investigate the expression of F-box protein 31 (FBXO31) and prospero-related homeobox 1 (PROX1) in ovarian cancer tissues and to analyze their correlations with pathological characteristics and prognosis,so as to provide a theoretical basis for pathological risk assessment,prognostic prediction,and the identification of potential therapeutic targets in ovarian cancer patients. Methods A total of 138 patients with ovarian cancer treated in our hospital from January 2019 to June 2021 were enrolled. According to survival status,patients were divided into a deceased group (n=59) and a survival group (n=79).The expression of FBXO31 and PROX1 was detected by immunohistochemistry.Cox proportional hazards regression analysis was used to identify factors influencing mortality.Kaplan-Meier survival analysis was performed to evaluate the effects of FBXO31 and PROX1 expression on overall survival in ovarian cancer patients. Results The proportions of negative FBXO31 expression and positive PROX1 expression were relatively high in ovarian cancer tissues (χ²=50.274 and 83.781,respectively,P＜0.05).Among patients with poorly differentiated tumors,lymph node metastasis,or TNM stage Ⅲ-Ⅳ,the proportion of negative FBXO31 expression was higher (χ²:4.524-12.644,P＜0.05),while the proportion of positive PROX1 expression was higher (χ²:6.072-10.107,P＜0.05).The prognosis of ovarian cancer patients was not associated with age,tumor size,or pathological type (P＞0.05).Poor differentiation (HR=1.756,95%CI:1.212-2.543),lymph node metastasis (HR=2.122,95%CI:1.398-3.221),TNM stage Ⅲ-Ⅳ (HR=2.472,95%CI:1.590-3.842),negative FBXO31 expression (HR=2.583,95%CI:1.735-3.845),and positive PROX1 expression (HR=2.044,95%CI:1.274-3.278) were all associated with an increased risk of mortality (P＜0.05).The survival rate for negative FBXO31 expression was 49.09%,lower than the 89.29% for positive expression (P＜0.05).The survival rate for positive PROX1 expression was 48.57%,lower than the 84.85% for negative expression (P＜0.05). Conclusion The expressions of FBXO31 and PROX1 in ovarian cancer tissues are associated with the pathological features of ovarian cancer. FBXO31 and PROX1 are influential factors in the prognosis of ovarian cancer patients.

关键词

卵巢癌 / F-box蛋白31 / Prospero相关同源盒蛋白1 / 病理特征 / 预后 / 相关性

Key words

ovarian cancer / F-box protein 31 / prospero-related homeobox 1 / pathological feature / prognosis / correlation

参考文献

[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] 陈李纲, 高云鸽, 董健, 等. 卵巢癌治疗中PARPi耐药机制及克服策略[J]. 中国妇幼健康研究, 2023, 34(7): 106-112.

[3] Zhang R, Siu M K Y, Ngan H Y S, et al. Molecular biomarkers for the early detection of ovarian cancer[J]. Int J Mol Sci, 2022, 23(19): 12041.

[4] 张焱, 王景美, 徐晓峰, 等. NACT对晚期卵巢癌的疗效及癌组织免疫组化表达的影响[J]. 中国妇幼健康研究, 2022, 33(1): 73-79.

[5] Duan S, Moro L, Qu R, et al. Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis[J]. Cell Rep, 2021, 37(3): 109870.

[6] Ntikoudi E, Pergaris A, Kykalos S, et al. The role of PROX1 in neoplasia:a key player often overlooked[J]. Diagnostics (Basel), 2022, 12(7): 1624.

[7] Ducoli L, Detmar M. Beyond PROX1:transcriptional,epigenetic,and noncoding RNA regulation of lymphatic identity and function[J]. Dev Cell, 2021, 56(4): 406-426.

[8] Zhu L, Tian Q, Gao H, et al. PROX1 promotes breast cancer invasion and metastasis through WNT/β-catenin pathway via interacting with hnRNPK[J]. Int J Biol Sci, 2022, 18(5): 2032-2046.

[9] 中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 490-500.

[10] 樊雷, 刘婧, 王婕. 宫颈癌组织FMNL3、ASAP1表达与患者临床病理特征、预后的关系[J]. 中国妇幼健康研究, 2025, 36(10): 14-20.

[11] Chen S, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050[J]. JAMA Oncol, 2023, 9(4): 465-472.

[12] Zeng L, Sun X. Correlation of INHBA overexpression with pathological features,antitumor immune response and clinical prognosis in cervical cancer[J]. Medicina (Kaunas), 2023, 59(3): 495.

[13] Svikle Z, Peterfelde B, Sjakste N, et al. Ubiquitin-proteasome system in diabetic retinopathy[J]. PeerJ, 2022, 10: e13715.

[14] Wang J, Xiang Y, Fan M, et al. The ubiquitin-proteasome system in tumor metabolism[J]. Cancers (Basel), 2023, 15(8): 2385.

[15] Liu Y, Pan B, Qu W, et al. Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer[J]. Cancer Cell Int, 2021, 21(1): 130.

[16] Meng J, Zhang C, Zhao T, et al. MicroRNA-210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β-catenin signaling pathway and EMT in esophageal squamous cell carcinoma[J]. Thorac Cancer, 2021, 12(6): 932-940.

[17] Yang M, Niu C. KLF9 regulated FBXO31 inhibits the progression of endometrial cancer and enhances the sensitivity of endometrial cancer cells to cisplatin[J]. Exp Ther Med, 2023, 27(2): 54.

[18] Ge Q, Li J, Yang F, et al. Molecular classifications of prostate cancer:basis for individualized risk stratification and precision therapy[J]. Ann Med, 2023, 55(2): 2279235.

[19] Li C, Liu F Y, Shen Y, et al. Research progress on the mechanism of glycolysis in ovarian cancer[J]. Front Immunol, 2023, 14: 1284853.

[20] Gan L, Li Q, Nie W, et al. PROX1-mediated epigenetic silencing of SIRT3 contributes to proliferation and glucose metabolism in colorectal cancer[J]. Int J Biol Sci, 2023, 19(1): 50-65.

基金资助

河北省卫生健康委员会资助项目(20221836)